At the news
? NEUTRALIMPACT 6/10 6-K filed Aug 18, 2026 at 07:04 ET
Immatics reported Q2 2026 financial results showing a net loss of €62.5M ($71.2M) on collaboration revenue of €9.1M ($10.4M), with R&D expenses rising sharply to €62.4M ($71.1M) as the Phase 3 SUPRAME trial accelerates. Enrollment remains on track to complete by year-end, but PFS events are occurring slower than modeled, prompting a streamlined final analysis (topline H1 2027) and adding ~90 patients for OS power. Cash and financial assets stood at €393.4M ($448.2M), projected into 2028.
- Q2 2026 revenue: €9.1M ($10.4M) from collaboration agreements (Moderna €6.5M, BMS €2.7M)
- Q2 2026 net loss: €62.5M ($71.2M), improved from €70.3M ($80.1M) in Q2 2025
- Cash and financial assets: €393.4M ($448.2M) as of June 30, 2026; cash reach projected into 2028
- SUPRAME enrollment on track to complete randomizations by year-end; PFS events occurring slower than modeled
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access